DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2001 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: esomeprazole magnesium

Summary for Generic Name: esomeprazole magnesium

Tradenames:1
Patents:16
Applicants:1
NDAs:1
Drug Master File Entries: see list41
Suppliers: see list12
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: esomeprazole magnesium

Tentative approvals for ESOMEPRAZOLE MAGNESIUM

Applicant Application No. Form Dosage
<disabled><disabled>CAPSULE, DELAYED RELEASE; ORAL20MG
<disabled><disabled>CAPSULE, DELAYED RELEASE; ORAL40MG

Clinical Trials for: esomeprazole magnesium

Viokase 16, Viokase16 Plus Nexium and Nexium Alone
Status: Terminated Condition: Chronic Pancreatitis

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
Status: Completed Condition: Heartburn; Gastroesophageal Reflux Disease

Nexium Study To Suppress Nausea During Chemotherapy
Status: Terminated Condition: Nausea

Prevention of Gastric Ulcers
Status: Completed Condition: NSAID Associated Gastric Ulcers

Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers
Status: Completed Condition: Healthy

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
Status: Completed Condition: Arthritis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Litigation for: ESOMEPRAZOLE


Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Patented / Exclusive Use
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes<disabled>NEW PRODUCT
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes4,255,431<disabled>GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING 'PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE'
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes4,508,905<disabled>
Astrazeneca
NEXIUM
esomeprazole magnesium
Capsule, Delayed Rel Pellets; Oral021153FEB 20, 2001RXYes4,636,499<disabled>GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING 'PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE'
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc